Table 1.
Baseline descriptive characteristics by maximum LOT received.
| Characteristic | No Chemotherapy (n = 1,035) |
LOT1 Only (n = 514) |
LOT1 & LOT2 Only (n = 209) |
LOT3+ (n = 115) |
P-value, LOT3+ vs No Chemotherapy |
|---|---|---|---|---|---|
| Age at diagnosis, median (IQR), years | 80 (74–84) | 74 (70–80) | 73 (70–78) | 73 (69–77) | < .001 |
| Male, n (%) | 618 (59.7) | 332 (64.6) | 154 (73.7) | 78 (67.8) | .091 |
| Race/ethnicity, n (%) | |||||
| Non-Hispanic white | 851 (82.2) | 441 (85.8) | 180 (86.1) | 105 (91.3) | .053 |
| Non-Hispanic black | 99 (9.6) | 33 (6.4) | NR | NR | |
| Hispanic | 59 (5.7) | 19 (3.7) | NR | NR | |
| Other | 26 (2.5) | 21 (4.1) | 15 (7.2) | NR | |
| Marital status at diagnosis, n (%) | |||||
| Single (never married) | 99 (9.6) | 32 (6.2) | NR | NR | < .001 |
| Married | 456 (44.1) | 315 (61.3) | 149 (71.3) | 74 (64.3) | |
| Separated/divorced/widowed | 446 (43.1) | 153 (29.8) | 41 (19.6) | 27 (23.5) | |
| Unknown | 34 (3.3) | 14 (2.7) | NR | NR | |
| Census location, n (%) | |||||
| West | 438 (42.3) | 227 (44.2) | 100 (47.8) | 46 (40.0) | .229 |
| South | 238 (23.0) | 104 (20.2) | 38 (18.2) | 19 (16.5) | |
| Northeast | 229 (22.1) | 116 (22.6) | 42 (20.1) | 32 (27.8) | |
| Midwest | 130 (12.6) | 67 (13.0) | 29 (13.9) | 18 (15.7) | |
| Charlson Comorbidity Index, n (%) | |||||
| 0 | 440 (42.5) | 252 (49.0) | 103 (49.3) | 63 (54.8) | .045 |
| 1 | 261 (25.2) | 125 (24.3) | 58 (27.8) | 27 (23.5) | |
| 2 | 154 (14.9) | 69 (13.4) | 27 (12.9) | NR | |
| 3+ | 180 (17.4) | 68 (13.2) | 21 (10.1) | NR | |
| Poor performance status, n (%) | 311 (30.0) | 109 (21.2) | 36 (17.2) | 22 (19.1) | .014 |
| TNM classification, n (%) | |||||
| M1 | 614 (59.3) | 207 (40.3) | 89 (42.6) | 53 (46.1) | .006 |
| T4b | 183 (17.7) | 71 (13.8) | 24 (11.5) | 23 (20.0) | .538 |
| N1–N3 | 462 (44.6) | 341 (66.3) | 128 (61.2) | 61 (53.0) | .086 |
| Topographic location of tumor, n (%) | |||||
| Lateral wall of bladder | 106 (10.2) | 58 (11.3) | 22 (10.5) | 14 (12.2) | .009 |
| Anterior wall of bladder | 21 (2.0) | 13 (2.5) | NR | NR | |
| Posterior wall of bladder | 56 (5.4) | 22 (4.3) | NR | NR | |
| Trigone of bladder | 64 (6.2) | 34 (6.6) | 20 (9.6) | NR | |
| Dome of bladder | 32 (3.1) | 24 (4.7) | NR | NR | |
| Bladder neck | 20 (1.9) | 22 (4.3) | 11 (5.3) | NR | |
| Ureter | 88 (8.5) | 37 (7.2) | 19 (9.1) | 18 (15.7) | |
| Overlapping lesion of bladder | 200 (19.3) | 107 (20.8) | 31 (14.8) | 14 (12.2) | |
| Bladder, NOS | 411 (39.7) | 176 (34.2) | 84 (40.2) | 35 (30.4) | |
| Ureteric orifice | 17 (1.6) | 13 (2.5) | NR | NR | |
| Urethra | 17 (1.6) | NR | NR | NR | |
| Kidney | NR | NR | NR | NR | |
| Renal pelvis | NR | NR | NR | NR |
Abbreviations. IQR, interquartile range; LOT, line of therapy; NOS, not otherwise specified; NR, not reported per the data use agreement with the National Cancer Institute that numbers less than 11 must be suppressed, and percentages or other mathematical formulas may not be used if they allow for the derivation of counts less than 11